Deucravacitinib safety during pregnancy study
Treatments studied
Part of Skin clinical trials.
This study looks at how safe the medicine deucravacitinib (used for psoriasis) is during pregnancy. It compares pregnant women who took deucravacitinib to those who did not, to see if there are any effects on the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently pregnant.
- You have psoriasis (confirmed by medical records if possible).
- For the deucravacitinib-exposed group: you took deucravacitinib at any time from 2 days before conception through the end of pregnancy.
- You agree to interviews, release of medical records, and a special exam of your baby after birth (for live births).
- You have not had a positive test for a major birth defect before joining the study.
- You have not used methotrexate or oral retinoids during pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.